The majority of patients were female (59.1% vs. 66.7% vs. 63.0%, p = 0.796), adenocarcinoma (100% vs. 98.6% vs. 96.3%, p = 0.648), stage IV (100% vs. 95.8% vs. 88.9%, p = 0.236), and EGFR 19DEL mutation (63.6% vs. 52.8% vs. 51.9%, p = 0.642) in the three groups. Here, EGFR is linked to adenocarcinoma.